Year In Review 2020

The Surfers and guests discuss key lessons learned in 2020 about Drugs and Diagnostics, and Patient Treatment and Perspectives.

2020 Year-End NASH Review 1: Drugs and Diagnostics

The Surfers and guests Vlad Ratziu and Mazen Noureddin discuss key lessons learned in 2020 about Drugs and Diagnostics

43.1 – 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics

Vlad Ratziu discusses a “boiling hot” field of emerging NASH drugs and “particularly rich” data coming from no-invasive diagnostic testing

43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in Fatty Liver Disease

Mazen Noureddin describes a year in which biopsy’s shortcomings are revealed at the same time as non-invasive testing becomes better and produces more robust data

43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals

Stephen Harrison summarizes a year of progress in improving the tests and analyses used to derive clinical endpoints necessary to initial drug approvals

Ep. 5 WILD TIMES IN NASH-VILLE: PART 1

Clinical trial results that are changing how we look at NASH

Ep. 6 “WHAT’S IN A NAME?”

Exploring the controversy over the name(s) to use when describing Fatty Liver disease(s)

Ep. 7 WILD TIMES IN NASH-VILLE PART 2

Reviewing press releases reporting preliminary findings from six recently announced Phase 2 trials

Ep. 8 Diagnosing Diagnostics – Part 1

Room for improvement